Reductions were also seen for neonatal intensive care unit admissions (10%), overall length of stay (7%), and the number of newborns with high morbidity burden (23%). Sensitivity analyses confirmed robustness of the model and showed the importance of treatment effectiveness in assessing whether the risk-screening-and-treat strategy would be cost saving.
This study is one of the first economic evaluations using real-world data to assess the potential value of the PreTRM test for preterm birth risk in a commercially insured US population. More than $850 million could be saved annually assuming full uptake of the risk-screen-and-treat strategy and 4 million births. Such a combination of better outcomes at lower costs is rare in modern healthcare.
Together with Elevance Health and Sera Prognostics, Carelon Research is currently working on the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study: a pragmatic clinical trial that will provide a blueprint for how the healthcare industry can more effectively identify and manage high-risk pregnancies and reduce preterm birth and its sequela.
Contingent on the results of these studies, Elevance Health will be making the test available to pregnant members — more than 10 percent of US pregnancies annually — as part of a multi-year contract with Sera.
The results of this study were presented at Virtual ISPOR 2021 and published in ClinicoEconomics and Outcomes Research.
For more information about our health economics & outcomes research capabilities, including project management, literature reviews, data management, large and complex database analytics, machine learning, patient and provider outreach, medical record review and abstraction, and survey-based-research, visit our Health Economics & Outcomes Research page.